Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
about
Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published dataRecombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use.Recombinant factor VIIa use in patients presenting with intracranial hemorrhage.Expression of recombinant human coagulation factor VII by the Lizard Leishmania expression system.Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trialsEvaluation of recombinant factor VIIa treatment for massive hemorrhage in patients with multiple traumasRecombinant factor VIIa in the treatment of non-hemophiliac bleeding.The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.The implementation of rapid cooling and overnight hold of whole blood at ambient temperature before processing into components in Israel.Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series.Recombinant activated factor VII (rFVIIa/NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome.
P2860
Q31146886-69285FBF-7442-45D7-A2BC-27A94E7C373FQ33633854-24770437-ECBD-454A-B36B-FBEEFC41DC4CQ34135771-7504C4D1-EDFB-402B-ACCC-31854192D1B9Q35202023-7CB1CD5B-B1D1-467F-91AD-CA69EBF27334Q35629970-079992A9-86EB-4B99-82BA-9C8122237E6DQ35788608-58070E76-6721-441E-A5D0-051FD7BFADF1Q36077574-523D4BB3-ABBE-4296-BFEA-93242373F0F7Q36150578-75BC88A4-AF5A-441E-82B0-3CAF76B4655BQ36284640-65F65FD3-B3AE-49B4-B994-20DE9773C303Q37691716-7165FD8E-E7C4-4C3F-B07C-59306D3C80A8Q45207216-04A4F7F2-DFDB-46C1-84E9-FFCA07F3146DQ47324534-83C48F5E-E51E-4D78-9540-B42C9ED00896Q50547561-FD353887-EEAF-41F3-90BD-080DDA5EA828Q50664916-91B354FE-BE7F-4550-8AB0-290BAC5CDB18Q50746970-8C91E84E-F489-49AA-BF75-AFC4B70C34B5
P2860
Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Recombinant activated factor V ...... and life-threatening bleeding.
@ast
Recombinant activated factor V ...... and life-threatening bleeding.
@en
type
label
Recombinant activated factor V ...... and life-threatening bleeding.
@ast
Recombinant activated factor V ...... and life-threatening bleeding.
@en
prefLabel
Recombinant activated factor V ...... and life-threatening bleeding.
@ast
Recombinant activated factor V ...... and life-threatening bleeding.
@en
P2093
P2860
P1433
P1476
Recombinant activated factor V ...... and life-threatening bleeding.
@en
P2093
J Klausner
R Geenberg
P2860
P356
10.1111/J.1423-0410.2004.00533.X
P577
2004-07-01T00:00:00Z